• Bliss GVS acquisition: Anupam Rasayan plans to acquire up to a 74% promoter stake in Bliss GVS via a multi-stage transaction to build an integrated pharma platform and expand market reach across Europe, the US, and India.
• Operational turnaround targets: Management aims to raise Bliss GVS's capacity utilization from approximately 30% to 70–80% over the next two to three years, targeting EBITDA margins in the 20% range.
• Debt and funding: The ₹2,200 crore transaction will add only ₹300 crore to company debt, taking consolidated net debt from ₹1,100 crore to around ₹1,400 crore, with the remainder funded via quasi-equity.
• Operating margin guidance: Despite Q4 margins dropping to 22%, the company guided for sustainable full-year EBITDA margins in the range of 25% (plus or minus 200 basis points).
• Future M&A pipeline: After completing two acquisitions within the calendar year, management confirmed there are no further inorganic acquisitions currently on the horizon.